Evidence map›Paper›PMID 40959381›Full record

ArticleToxicology reports2025

Immune-related adverse events in immunotherapy: Challenges in diagnosis, monitoring, and management.

Mohd Aftab Siddiqui, Afreen Usmani, Mohd Nazam Ansari, Rania I M Almoselhy

Abstract read
In one paragraph

Article in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohd Aftab SiddiquiFaculty of Pharmacy, Integral University, Lucknow, U.P., India.
Afreen UsmaniMESCO Institute of Pharmacy, Amroha, U.P., India.
Mohd Nazam AnsariDepartment of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia.
Rania I M AlmoselhyOils and Fats Research Department, Food Technology Research Institute, Agricultural Research Center, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article provides a comprehensive overview of safety and monitoring guidelines in immunotherapy, a rapidly advancing field in cancer and autoimmune treatment. Immunotherapy, which harnesses the body's immune system to combat diseases, has shown remarkable promise but presents unique safety challenges requiring rigorous oversight. The article examines various immunotherapies, including immune checkpoint inhibitors, monoclonal antibodies, and cytokine therapies, highlighting potential adverse effects and the critical need for careful monitoring. It emphasizes pre-treatment assessments, risk stratification, and genetic and biomarker screening to identify high-risk patients. Detailed monitoring protocols, including laboratory tests, imaging, and clinical evaluations, are discussed to detect immune-related adverse events (irAEs) early. Strategies for managing both acute and chronic toxicities, such as dose adjustments and treatment interruptions, are outlined to ensure timely intervention and individualized care. The article also underscores the importance of patient education, compliance, and supportive care, emphasizing a multidisciplinary approach. Through this detailed review, healthcare professionals gain practical guidelines to optimize the safe and effective use of immunotherapies in clinical settings.

Indexed as

Immune-Related Adverse Events (irAEs)Immunotherapy SafetyMonitoring ProtocolsPatient Education and SupportRisk StratificationToxicity Management

Identifiers

PMID40959381
PMCPMC12433800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.